Data / Research funding / Cannabidiol Research
Cannabidiol Research: 152 NIH awards ($216.2M) to 78 organizations
152 NIH awards ($216.2M) in the NIH spending category Cannabidiol Research, to 78 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
152 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Cannabidiol in the treatment of opioid use disorder | NIH | National Institute on Drug Abuse | 2024 | $10,316,590 | September 30, 2019 | August 31, 2027 | HURD, YASMIN L. | reporter.nih.gov |
| LifeâÂÂs end Benefits of CannaBidol and TetrahYdrocannabinol (LiBBY) Trial | NIH | National Institute on Aging | 2021 to 2022 | $9,892,823 | September 15, 2020 | April 30, 2026 | MINTZER, JACOBO | reporter.nih.gov |
| Rocky Mountain Cannabis Research Center | NIH | National Institute on Drug Abuse | 2023 to 2025 | $8,380,548 | September 1, 2023 | June 30, 2028 | HUTCHISON, KENT E. | reporter.nih.gov |
| Elucidating single cell changes in neurogenic brain regions during HIV and cannabinoid exposure | NIH | National Institute on Drug Abuse | 2023 to 2025 | $7,084,951 | May 15, 2023 | March 31, 2028 | NDHLOVU, LISHOMWA C | reporter.nih.gov |
| Translational Studies of Cannabis Administration, Cognition, and the Endocannabinoid System in HIV | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,324,439 | May 1, 2021 | July 31, 2026 | MINASSIAN, ARPI | reporter.nih.gov |
| Evaluation of Cannabidiol for Reduction of Brain Neuroinflammation | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,931,875 | June 1, 2021 | March 31, 2027 | LOGGIA, MARCO LUCIANO | reporter.nih.gov |
| PRODUCTION, ANALYSIS, AND DISTRIBUTION OF CANNABIS AND RELATED MATERIALS. POP: MARCH 23, 2015 - MARCH 22, 2023. N01DA-15-7793. | NIH | National Institute on Drug Abuse | 2021 to 2022 | $3,928,369 | March 23, 2015 | March 22, 2023 | ELSOHLY, MAHMOUD | reporter.nih.gov |
| Cannabis and Pathogenic Mechanisms influencing Blood Brain Barrier Function in HIV | NIH | National Institute on Drug Abuse | 2023 to 2025 | $3,726,178 | August 15, 2023 | June 30, 2028 | IUDICELLO, JENNIFER E | reporter.nih.gov |
| Effects of Cannabidiol and Tetrahydrocannabinol on the Microbiome, Endocannabinoids and Neuroinflammation in HIV | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,584,464 | June 15, 2022 | March 31, 2027 | ELLIS, RONALD J. | reporter.nih.gov |
| Cannabidiol for postoperative Opioid Reduction in primary total Knee arthroplasty – a randomized, 2x2 factorial, double-blind, placebo-controlled clinical trial (The CORK trial) | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $3,579,362 | September 18, 2023 | August 31, 2028 | BRUMMETT, CHAD M | reporter.nih.gov |
| Molecular underpinnings of the developmental Effects of Cannabis | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,375,521 | August 15, 2022 | May 31, 2027 | HURD, YASMIN L. | reporter.nih.gov |
| Epigenetic mechanisms underlying cannabinoid modulation of neuroinflammation in HIV/SIV infection | NIH | National Institute on Drug Abuse | 2021 to 2024 | $3,267,557 | September 30, 2020 | June 30, 2026 | MOHAN, MAHESH | reporter.nih.gov |
| Effects of full-spectrum cannabidiol on alcohol consumption and alcohol use disorder phenotypes: implications for precision medicine | NIH | National Institute on Alcohol Abuse and Alcoholism | 2025 | $3,227,517 | September 20, 2025 | August 31, 2029 | KAROLY, HOLLIS C | reporter.nih.gov |
| ERP studies of acute influences of THC and CBD on memory encoding and retrieval processes | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,173,683 | August 1, 2021 | May 31, 2027 | CURRAN, TIMOTHY E | reporter.nih.gov |
| Discriminative Stimulus Effects of Opioid Withdrawal | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,097,773 | May 1, 1995 | December 31, 2026 | FRANCE, CHARLES P | reporter.nih.gov |
| Cannabis use among older adults: Potential risks and benefits to an aging population | NIH | National Institute on Aging | 2021 to 2025 | $3,055,285 | February 15, 2021 | January 31, 2027 | BRYAN, ANGELA | reporter.nih.gov |
| Development of KLS-13019 for Neuropathic Pain | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $2,970,772 | September 30, 2021 | August 31, 2025 | BRENNEMAN, DOUGLAS ERIC | reporter.nih.gov |
| Cannabis, HIV and Mental Processing Systems (CHAMPS) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,959,350 | August 1, 2021 | May 31, 2027 | ANCES, BEAU M | reporter.nih.gov |
| Mechanism and optimization of CBD-mediated analgesic effects (Diversity Supplement) | NIH | National Center for Complementary & Integrative Health | 2021 to 2023 | $2,902,023 | September 15, 2019 | June 30, 2025 | HE, ZHIGANG | reporter.nih.gov |
| Optimization of Cannabinoids for Development as FDA-Approved Migraine Therapeutics | NIH | National Institute on Drug Abuse | 2024 to 2025 | $2,883,639 | September 30, 2020 | August 31, 2026 | PAPPAS, GEORGE | reporter.nih.gov |
| Cannabinoid interactions with central and peripheral pain mechanisms in osteoarthritis of the knee | NIH | National Center for Complementary & Integrative Health | 2021 to 2024 | $2,864,374 | August 1, 2020 | May 31, 2026 | HARTE, STEVEN EDWARD | reporter.nih.gov |
| Opioid and cannabinoid interactions in pain and reward | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,852,096 | September 30, 2020 | June 30, 2026 | NEUBERT, JOHN K | reporter.nih.gov |
| Mechanism of Cannabidiol Effects on HIV Expression, Neuroinflammation, and HIV Cognitive Disease in Chronically-infected Immunocompetent Mice | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,851,386 | September 30, 2020 | July 31, 2025 | VOLSKY, DAVID J | reporter.nih.gov |
| Cannabis Effects on Antiretroviral Therapy, Pharmacokinetics, and Neurotoxicity | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,756,681 | July 1, 2020 | April 30, 2026 | LETENDRE, SCOTT L | reporter.nih.gov |
| Mechanisms of cannabidiol in persons with MS: the role of sleep and pain phenotype | NIH | National Center for Complementary & Integrative Health | 2021 to 2024 | $2,725,289 | August 15, 2021 | May 31, 2026 | BRALEY, TIFFANY JOY | reporter.nih.gov |
| Cannabis' Impact on Alcohol Consumption: Integrating Laboratory and Ecological Momentary Assessment Methods | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $2,671,024 | April 1, 2022 | March 31, 2027 | METRIK, JANE | reporter.nih.gov |
| Cannabis use frequency and its impact on monocyte-mediated inflammation in HIV patients | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,570,020 | September 1, 2021 | July 31, 2027 | KAMINSKI, NORBERT E | reporter.nih.gov |
| Drug-gene-nutraceutical interactions of cannabidiol | NIH | National Center for Complementary & Integrative Health | 2022 to 2025 | $2,519,234 | February 22, 2022 | January 31, 2027 | EADON, MICHAEL THOMAS | reporter.nih.gov |
| Novel Approaches to Opiate Use Reduction | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,469,078 | April 1, 2020 | January 31, 2026 | HUTCHISON, KENT E. | reporter.nih.gov |
| Hemp-derived Cannabidiol for the treatment of cannabis use disorder in concentrate users: A double-blind placebo-controlled randomized trial | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,376,018 | September 15, 2023 | July 31, 2028 | BIDWELL, L. CINNAMON | reporter.nih.gov |
| Translating CBD Treatment for Heroin Addiction | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,349,864 | August 1, 2019 | June 30, 2025 | HURD, YASMIN L. | reporter.nih.gov |
| Quorum Sensing Regulation of EHEC Virulence Genes | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,346,135 | January 1, 2023 | December 31, 2027 | SPERANDIO, VANESSA | reporter.nih.gov |
| Looking into the Heart of Cannabis and HIV | NIH | National Institute on Drug Abuse | 2022 | $2,302,500 | April 1, 2022 | March 31, 2026 | MARTINEZ, CLAUDIA | reporter.nih.gov |
| The Impact of Cannabidiol (CBD) Health Claims at Point-of-Sale on Consumer Perceptions and Behavior | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,287,873 | July 15, 2021 | May 31, 2027 | WAGONER, KIMBERLY G. | reporter.nih.gov |
| Cannabidiol and Macrophage Chronic Inflammation in a Virally Suppressed Rhesus Macaque Model | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,266,058 | September 30, 2020 | June 30, 2025 | WILLIAMS, DIONNA WHITNEY | reporter.nih.gov |
| The Effects of Cannabinoids and Route of Cannabis Administration on Subclinical Cardiovascular Disease Risk | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,169,132 | August 1, 2020 | June 30, 2025 | VIDOT, DENISE CHRISTINA | reporter.nih.gov |
| Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial | NIH | National Institute on Aging | 2023 to 2025 | $2,143,253 | July 1, 2023 | June 30, 2028 | HUTCHISON, KENT E. | reporter.nih.gov |
| Development of cannabinoid-opioid combination with opioid sparing and synergistic analgesic effects to prevent opioid use disorder and overdose. | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,110,556 | September 30, 2019 | August 31, 2025 | BRIONES, MARISA | reporter.nih.gov |
| Brain and behavior correlates of prenatal cannabis exposure | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,095,376 | July 15, 2023 | May 31, 2028 | KLEINHANS, NATALIA M | reporter.nih.gov |
| Life’s end Benefits of CannaBidiol and TetrahYdrocannabinol (LiBBY) Open-Label Extension (OLE) Study | NIH | National Institute on Aging | 2025 | $2,072,617 | August 15, 2025 | July 31, 2028 | MINTZER, JACOBO | reporter.nih.gov |
| Cannabidiol/Palmitoylethanolamide sublingual tablets for the treatment of Painful Diabetic Peripheral Neuropathy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $2,051,325 | September 20, 2023 | July 31, 2025 | KIMLESS, DEBRA | reporter.nih.gov |
| Preclinical Assessment of Medications for Alcohol Abuse | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $2,042,668 | September 28, 2007 | March 31, 2025 | WEERTS, ELISE M | reporter.nih.gov |
| Alcohol Use Disorder and Cannabis: Testing Novel Harm Reduction Strategies | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $2,030,405 | April 20, 2022 | March 31, 2027 | HUTCHISON, KENT E. | reporter.nih.gov |
| Modeling the effects of chronic marijuana use on neuroinflammation and HIV-related neuronal injury | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,976,642 | September 30, 2020 | June 30, 2023 | MEADE, CHRISTINA S | reporter.nih.gov |
| Cannabis for Palliative Care in Cancer: A Placebo-controlled Randomized Trial of Full Spectrum Hemp-derived CBD/THC | NIH | National Cancer Institute | 2023 to 2025 | $1,915,200 | August 1, 2023 | July 31, 2028 | BRYAN, ANGELA | reporter.nih.gov |
| Mechanisms and treatment of adolescent phytocannabinoid impairment of prefrontal cortex function | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,784,987 | May 1, 2022 | February 28, 2027 | LU, HUI-CHEN | reporter.nih.gov |
| Cannabidiol and terpenoid interactions in amygdalar regulation of pain states | NIH | National Center for Complementary & Integrative Health | 2022 to 2025 | $1,717,472 | May 1, 2022 | January 31, 2027 | LAND, BENJAMIN | reporter.nih.gov |
| Cannabidiol-enhanced cognitive behavioral therapy for generalized anxiety disorder | NIH | National Institute of Mental Health | 2025 | $1,715,387 | June 1, 2025 | May 31, 2027 | MARUSAK, HILARY | reporter.nih.gov |
| Cannabis use and cardiovascular health outcomes among patients with high blood pressure | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,692,524 | September 15, 2023 | July 31, 2028 | ALSHAARAWY, OMAYMA O | reporter.nih.gov |
| Neuro-immune mechanisms of minor cannabinoids in inflammatory and neuropathic pain | NIH | National Center for Complementary & Integrative Health | 2021 to 2023 | $1,692,291 | September 15, 2019 | June 30, 2025 | HELLMAN, JUDITH | reporter.nih.gov |
| Exploring the anti-inflammatory properties of cannabis and their relevance to insulin sensitivity | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,652,097 | September 1, 2019 | May 31, 2026 | BRYAN, ANGELA | reporter.nih.gov |
| Dravet Syndrome Anti-Epileptic Control by Targeting GIRK Channels | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,645,372 | March 1, 2023 | December 31, 2027 | LOGOTHETIS, DIOMEDES E. | reporter.nih.gov |
| Enhanced APOE2 Expression into Brain for Therapeutic Strategy for Alzheimer's Disease | NIH | National Institute on Aging | 2021 to 2022 | $1,628,551 | May 15, 2021 | April 30, 2024 | SINGH, JAGDISH | reporter.nih.gov |
| Modeling the effects of chronic marijuana use on neuroinflammation and HIV-related neuronal injury | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,527,736 | September 30, 2020 | August 31, 2026 | MEADE, CHRISTINA S | reporter.nih.gov |
| Define the effects and mechanism of THC and CBD on IFN-I mediated inflammation and immune dysfunction during HIV infection | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,482,000 | September 30, 2020 | July 31, 2025 | ZHEN, ANJIE | reporter.nih.gov |
| Targeting autophagy to reduce inflammasome-mediated inflammation and immune dysfunction in HIV and methamphetamine use | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,416,081 | June 1, 2024 | March 31, 2029 | ZHEN, ANJIE | reporter.nih.gov |
| Biosynthesis and biological mechanism of minor cannabinoids | NIH | National Center for Complementary & Integrative Health | 2024 to 2025 | $1,373,136 | December 20, 2023 | October 31, 2028 | MOORE, BRADLEY S | reporter.nih.gov |
| Clinical Trial of Maternal Choline Supplements to Mitigate Effects of Prenatal Cannabis Exposure on Early Brain Development. | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,348,364 | May 1, 2024 | February 28, 2029 | HUNTER, SHARON K | reporter.nih.gov |
| Repeated Administration of Cannabis Varying in THC and CBD: Effects on Abuse Liability, Experimental Pain and Plasma Endocannabinoids | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,341,614 | August 15, 2022 | May 31, 2028 | HANEY, MARGARET | reporter.nih.gov |
| Health effects of cannabidiol vaping products | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,323,987 | March 1, 2024 | December 31, 2027 | REBULI, MEGHAN ELIZABETH | reporter.nih.gov |
| Cannabis use and the endocannabinoid system in bipolar disorder | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,310,628 | May 1, 2018 | February 29, 2024 | PERRY, WILLIAM | reporter.nih.gov |
| Psychopharmacological effects of cannabidiol on responses to stress and nicotine withdrawal | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,303,839 | September 30, 2010 | February 28, 2029 | AL'ABSI, MUSTAFA | reporter.nih.gov |
| Analgesic efficacy of single and combined minor cannabinoids and terpenes | NIH | National Center for Complementary & Integrative Health | 2021 to 2023 | $1,188,750 | September 15, 2019 | June 30, 2025 | WARD, SARA J | reporter.nih.gov |
| Randomized placebo controlled trial to determine the biological signature of cannabidiol as a treatment for social anxiety disorder | NIH | National Center for Complementary & Integrative Health | 2022 to 2023 | $1,180,991 | September 19, 2022 | February 28, 2026 | SIMON, NAOMI M | reporter.nih.gov |
| Endocannabinoid System Engagement and Clinical Symptom Change with Cannabidiol for Social Anxiety Disorder | NIH | National Center for Complementary & Integrative Health | 2022 to 2023 | $1,099,216 | January 18, 2022 | April 30, 2025 | TAYLOR, CHARLES | reporter.nih.gov |
| Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2022 | $1,083,127 | May 15, 2019 | November 30, 2024 | LONDON, EDYTHE DANICK | reporter.nih.gov |
| The GPR171 pathway in cancer immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $1,049,334 | April 25, 2023 | March 31, 2028 | ZHU, YUWEN | reporter.nih.gov |
| Anti-inflammatory Effects of Novel Minor Cannabinoids and Terpenes on Cellular and Murine Models of HIV and HIV Proteins | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,034,538 | September 30, 2020 | July 31, 2025 | PARIS, JASON RICHARD | reporter.nih.gov |
| Effects of Early-life Cannabinoid Exposure on Prefrontal Circuitry and Cognitive Behavior across Development | NIH | National Institute on Drug Abuse | 2024 to 2025 | $967,695 | June 1, 2024 | March 31, 2029 | CHE, ALICIA YUE | reporter.nih.gov |
| Mentoring Clinical Researchers at the Intersection of NeuroHIV and Substance Abuse | NIH | National Institute on Drug Abuse | 2021 to 2025 | $959,325 | July 1, 2015 | June 30, 2027 | CHERNER, MARIANA | reporter.nih.gov |
| Cannabidiol Pharmacotherapy for Comorbid Opioid Addiction and Chronic Pain | NIH | National Institute on Drug Abuse | 2021 to 2025 | $958,500 | May 1, 2021 | April 30, 2026 | DE AQUINO, JOAO PAULO | reporter.nih.gov |
| State-dependent interaction of antiepileptic drugs with voltage-dependent sodium channels and differential regulation of excitatory and inhibitory central neurons | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $949,316 | February 1, 2019 | January 31, 2024 | BEAN, BRUCE P | reporter.nih.gov |
| The Effects of Cannabidiol on the Driving Performance of Healthy Adults | NIH | National Institute on Drug Abuse | 2024 to 2025 | $920,550 | September 1, 2024 | May 31, 2029 | RUDISILL, TONI MARIE | reporter.nih.gov |
| Vulnerability and Persistence of Neuroinflammation and Behavioral Deficits from Developmental Cannabinoid Exposure | NIH | National Institute on Drug Abuse | 2024 to 2025 | $885,374 | July 1, 2024 | May 31, 2029 | WILLETT, KRISTINE L | reporter.nih.gov |
| Combination of THC and CBD as a Novel Treatment for Co-Occurring Opioid Addiction and Chronic Pain | NIH | National Institute on Drug Abuse | 2024 to 2025 | $883,050 | May 1, 2024 | February 28, 2028 | DE AQUINO, JOAO PAULO | reporter.nih.gov |
| Pathophysiological mechanisms of cannabidiol in stress regulation | NIH | National Institute of Mental Health | 2025 | $794,696 | May 1, 2025 | February 28, 2030 | BACHI, KEREN | reporter.nih.gov |
| Quantifying effects of comorbidities and genetics on cannabinoid exposure in the elderly | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $794,611 | August 1, 2022 | February 28, 2026 | ZHOU, ZHU | reporter.nih.gov |
| The impact of medical cannabis on pain and inflammation in people living with HIV | NIH | National Institute on Drug Abuse | 2021 to 2024 | $776,700 | July 15, 2021 | February 28, 2026 | SLAWEK, DEEPIKA | reporter.nih.gov |
| The role of TREM2 in Alzheimer's disease related neuropathogenesis in people with HIV | NIH | National Institute on Aging | 2025 | $768,131 | July 1, 2025 | June 30, 2030 | FIELDS, JEREL ADAM | reporter.nih.gov |
| Antidotes for Acute Cannabinoid Intoxication | NIH | National Institute on Drug Abuse | 2021 to 2022 | $746,997 | September 30, 2018 | July 31, 2024 | MAKRIYANNIS, ALEXANDROS | reporter.nih.gov |
| Role of Macrophages in CBD mediated attenuation of SEB-induced ARDS | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $746,874 | February 1, 2022 | July 31, 2026 | WILSON, KIESHA | reporter.nih.gov |
| Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $746,308 | August 1, 2019 | August 31, 2023 | CAMILLERI, MICHAEL L. | reporter.nih.gov |
| Does medical cannabis reduce opioid analgesics in HIV+ and HIV- adults with pain? | NIH | National Institute on Drug Abuse | 2021 | $733,464 | July 1, 2017 | June 30, 2024 | ARNSTEN, JULIA H. | reporter.nih.gov |
| Oral THC consumption during adolescence and its impact on adult mouse brain | NIH | National Institute on Drug Abuse | 2025 | $716,455 | July 1, 2025 | March 31, 2030 | STELLA, NEPHI | reporter.nih.gov |
| Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving | NIH | National Institute on Alcohol Abuse and Alcoholism | 2025 | $672,377 | September 20, 2025 | August 31, 2030 | WOLINSKY, DAVID | reporter.nih.gov |
| Characterizing the Epidemiology of Cannabidiol (CBD) Use Among US adults | NIH | National Institute on Drug Abuse | 2022 to 2025 | $668,431 | April 1, 2022 | March 31, 2027 | LEAS, ERIC | reporter.nih.gov |
| An observational study of the effects of edible cannabis and its constituent cannabinoids on pain, inflammation, and cognition | NIH | National Center for Complementary & Integrative Health | 2021 | $654,019 | September 15, 2017 | August 31, 2024 | BIDWELL, L. CINNAMON | reporter.nih.gov |
| Cannabidiol and Macrophage Chronic Inflammation in a Virally Suppressed Rhesus Macaque Model | NIH | National Institute on Drug Abuse | 2024 | $640,462 | July 1, 2024 | June 30, 2026 | WILLIAMS, DIONNA WHITNEY | reporter.nih.gov |
| Perinatal cannabinoids delay KCC2 expression and lead to neurodevelopmental abnormalities | NIH | National Institute on Drug Abuse | 2021 to 2022 | $619,214 | August 1, 2018 | June 30, 2024 | MACKIE, KENNETH | reporter.nih.gov |
| Single cell dark matter in the context of HIV and substance use | NIH | National Institute on Drug Abuse | 2025 | $616,372 | July 15, 2025 | March 31, 2030 | NIXON, DOUGLAS F | reporter.nih.gov |
| Novel approaches to understanding the role of cannabinoids and inflammation in anxiety | NIH | National Institute on Drug Abuse | 2021 | $562,633 | September 1, 2017 | June 30, 2024 | BIDWELL, L. CINNAMON | reporter.nih.gov |
| Cannabinoids as an environmental risk factor of testicular cancer: Assessment using cell culture models of human and mouse primordial germ cells and by exposure of pregnant mice | NIH | National Institute on Drug Abuse | 2024 to 2025 | $473,500 | May 15, 2024 | April 30, 2027 | SHIODA, TOSHIHIRO | reporter.nih.gov |
| Cannabis Hyperemesis Syndrome: An Increasing Challenge in Emergency Care | NIH | National Institute on Drug Abuse | 2021 to 2022 | $465,775 | July 1, 2021 | June 30, 2024 | WIGHTMAN, RACHEL | reporter.nih.gov |
| Interaction of cannabidiol (CBD) with targeted inhibitors of essential cancer signaling pathways | NIH | National Cancer Institute | 2023 to 2024 | $454,926 | April 1, 2023 | March 31, 2026 | GOLEMIS, ERICA A. | reporter.nih.gov |
| A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy | NIH | National Cancer Institute | 2022 | $452,540 | September 23, 2022 | August 31, 2025 | LEE, RICHARD T | reporter.nih.gov |
| Structural Insights into TRPV Channel Gating | NIH | National Institute of General Medical Sciences | 2021 | $446,342 | August 1, 2013 | June 30, 2022 | MOISEENKOVA-BELL, VERA | reporter.nih.gov |
| The Developmental Effects of Environmental Enrichment on the Minor Cannabinoid Drug Reward and Cannabinoid Receptor Levels | NIH | National Institute on Drug Abuse | 2024 | $440,924 | August 1, 2024 | July 31, 2027 | STAIRS, DUSTIN JEFFREY | reporter.nih.gov |
| Negative allosteric modulation of mu opioid receptors to reverse fentanyl overdose | NIH | National Institute on Drug Abuse | 2024 to 2025 | $435,875 | September 15, 2024 | August 31, 2026 | MACKIE, KENNETH | reporter.nih.gov |
| Kratom and Cannabinoid Constituents: Mechanisms and Interactive Effects in Neuropathic Pain | NIH | National Center for Complementary & Integrative Health | 2023 | $433,710 | August 7, 2023 | July 31, 2025 | WARD, SARA J | reporter.nih.gov |
| Alteration of bronchial epithelium host defenses by marijuana and vaping preparations | NIH | National Institute on Drug Abuse | 2023 to 2024 | $433,125 | September 15, 2023 | August 31, 2025 | CORMET-BOYAKA, ESTELLE A | reporter.nih.gov |
| Mechanisms of cannabinoid-resistance among oral spirochetes | NIH | National Institute of Dental & Craniofacial Research | 2025 | $431,750 | July 15, 2025 | July 14, 2027 | SCOTT, DAVID A | reporter.nih.gov |
| Exploring the Neuroprotective Potential of CBD in Preventing Oxaliplatin-Induced Neuropathy: A Prospective Study | NIH | National Cancer Institute | 2025 | $429,162 | August 1, 2025 | July 31, 2027 | VIJAYVERGIA, NAMRATA | reporter.nih.gov |
| Studies of Cannabidiol in Neurodevelopment | NIH | National Institute on Drug Abuse | 2021 to 2022 | $429,000 | April 1, 2021 | March 31, 2024 | HILLARD, CECILIA J | reporter.nih.gov |
| Prenatal exposure to cannabis and child cardiometabolic health outcomes | NIH | National Institute on Drug Abuse | 2024 to 2025 | $429,000 | August 15, 2024 | July 31, 2027 | MOORE, BRIANNA F | reporter.nih.gov |
| Genetically Encoded Optical Biosensors for Dissecting Brain Distribution and Metabolism of Cannabinoids | NIH | National Institute on Drug Abuse | 2021 to 2022 | $427,625 | March 15, 2021 | February 29, 2024 | GU, LIANGCAI | reporter.nih.gov |
| Cannabinoid Effects on Sleep and Pain Mechanisms in Osteoarthritis of the Knee | NIH | National Institute on Drug Abuse | 2021 to 2023 | $427,278 | July 15, 2020 | June 30, 2024 | BOEHNKE, KEVIN FOXMAN | reporter.nih.gov |
| Regulation of Fat Taste by Adiposity and Endocannabinoids: Implications for Obesity | NIH | National Institute on Deafness and Other Communication Disorders | 2023 to 2024 | $426,361 | December 1, 2022 | November 30, 2025 | BRESLIN, PAUL A. S | reporter.nih.gov |
| Chronic effects of different THC:CBD ratios on executive function and emotional processing in people with multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $424,875 | December 1, 2021 | November 30, 2024 | GANDER, PHILLIP EVAN | reporter.nih.gov |
| Mechanism and Therapeutic Potential of CBD to Repair Blood-Brain Barrier Dysfunction in Epilepsy | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $420,750 | April 1, 2023 | March 31, 2026 | BAUER, BJOERN | reporter.nih.gov |
| Cannabidiol (CBD) as a Potential Therapeutic for Experimental Subarachnoid Hemorrhage | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $420,750 | December 5, 2023 | May 31, 2026 | ROBERTS, JILL MARIE | reporter.nih.gov |
| Cannabidiol as a treatment for alcoholic liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 | $411,257 | September 1, 2023 | August 31, 2025 | SONG, ZHAO-HUI | reporter.nih.gov |
| Computation-assisted discovery of bioactive minor cannabinoids from hemp | NIH | National Center for Complementary & Integrative Health | 2023 | $408,375 | September 25, 2023 | August 31, 2025 | STEVENS, JAN FREDERIK | reporter.nih.gov |
| Optimization of cannabidiol-based formulations in autism spectrum disorder | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $396,988 | January 1, 2025 | December 31, 2028 | KAPLAN, JOSH | reporter.nih.gov |
| Neurobehavioral effects of cannabidiol in youth alcohol use disorder | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2023 | $395,603 | June 1, 2022 | May 31, 2024 | SQUEGLIA, LINDSAY | reporter.nih.gov |
| Exploring the antecendents and consequences of cannabis use in the context of coping: An experimental study | NIH | National Institute on Drug Abuse | 2024 to 2025 | $390,405 | August 1, 2024 | July 31, 2029 | SKRZYNSKI, CARILLON JOY | reporter.nih.gov |
| The therapeutic effect of cannabigerol (CBG) with or without cannabidiol (CBD) in diet-induced non-alcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 | $377,986 | August 1, 2024 | July 31, 2027 | HAN, YUYAN | reporter.nih.gov |
| From the Scanner to the Clinic: Patient Oriented Research and Mentorship | NIH | National Institute on Drug Abuse | 2021 to 2023 | $363,456 | August 15, 2020 | July 31, 2026 | MARTINEZ, DIANA M | reporter.nih.gov |
| Cannabinoid control of epilepsy | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $350,775 | July 1, 2017 | March 31, 2023 | SOLTESZ, IVAN | reporter.nih.gov |
| Combination Therapeutic for Chronic Opioid Use Disorder Relapse | NIH | National Institute on Drug Abuse | 2023 | $335,700 | July 1, 2023 | June 30, 2025 | CASTOR, TREVOR P. | reporter.nih.gov |
| Pseudocannabinoids for mitigation of substance use disorder | NIH | National Institute on Drug Abuse | 2025 | $334,343 | June 15, 2025 | May 31, 2027 | MASCAL, MARK | reporter.nih.gov |
| Impact of cannabidiol on HIV infection and methamphetamine abuse associated neuroinflammation | NIH | National Institute on Drug Abuse | 2024 to 2025 | $307,000 | April 1, 2024 | March 31, 2027 | CHAND, SUBHASH | reporter.nih.gov |
| Neurocognitive implications of cannabidiol (CBD) while aging with HIV | NIH | National Institute on Drug Abuse | 2022 to 2023 | $295,000 | July 1, 2022 | June 30, 2025 | RODRIGUEZ, MYOSOTYS | reporter.nih.gov |
| Planning Grant for a Clinical Trial Of Cannabidiol For Postoperative Opioid Reduction in Primary Total Knee Arthroplasty | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $274,560 | August 2, 2021 | July 31, 2023 | BOEHNKE, KEVIN FOXMAN | reporter.nih.gov |
| Understanding cannabidiol policy and its impacts on broader substance use | NIH | National Institute on Drug Abuse | 2025 | $268,470 | April 15, 2025 | September 1, 2025 | POWELL, DAVID | reporter.nih.gov |
| Optimization of a nanoparticle-based topical PDE5i formulation for treatment of erectile dysfunction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 | $263,446 | September 15, 2022 | August 31, 2024 | DRAGANSKI, ANDREW R | reporter.nih.gov |
| Patient Oriented Research and Mentoring in Multidisciplinary Chronic Pain Treatments | NIH | National Center for Complementary & Integrative Health | 2024 to 2025 | $255,917 | September 6, 2024 | August 31, 2029 | KRATZ, ANNA LOUISE | reporter.nih.gov |
| Beta-caryophyllene (BCP) and cannabidiol (CBD) combination: HIV-1 chronic neuropathic pain | NIH | National Institute on Drug Abuse | 2021 to 2022 | $241,100 | September 30, 2021 | April 30, 2023 | BENAMAR, KHALID | reporter.nih.gov |
| Effect on CBD on Exosome release from CNS infected cells | NIH | National Institute on Drug Abuse | 2021 | $236,054 | May 1, 2020 | October 31, 2023 | KASHANCHI, FATAH | reporter.nih.gov |
| Impact on adult mouse brain of oral THC and CBD consumption during adolescence | NIH | National Institute on Drug Abuse | 2021 | $233,250 | July 15, 2020 | June 30, 2023 | STELLA, NEPHI | reporter.nih.gov |
| Functional efficacy of cannabidiol in modulating the adverse effects of heroin in primates. | NIH | National Institute on Drug Abuse | 2024 | $232,500 | August 1, 2024 | July 31, 2026 | KO, MEI-CHUAN | reporter.nih.gov |
| The impact of cannabinoids on inflammation, HIV viral load and symptoms of distress among persons living with HIV | NIH | National Institute on Drug Abuse | 2022 to 2023 | $229,556 | August 1, 2019 | July 31, 2025 | OKAFOR, CHUKWUEMEKA NKEMAKONAM | reporter.nih.gov |
| Chemoenzymatic synthesis and pharmacological evaluation of designer plant meroterpenoids | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $221,404 | April 1, 2023 | March 31, 2026 | LOVE, ANNA CLAIRE | reporter.nih.gov |
| Smartphone app to examine effects of cannabis use on driving behavior | NIH | National Institute on Drug Abuse | 2022 | $218,493 | July 1, 2022 | June 30, 2023 | CHUNG, TAMMY | reporter.nih.gov |
| Pilot Trial of CBD for Sleep in People with HIV | NIH | National Institute on Drug Abuse | 2021 | $197,500 | September 30, 2020 | August 31, 2023 | CHERNER, MARIANA | reporter.nih.gov |
| Cannabidiol (CBD)-only use in Pregnancy and Perinatal Outcomes | NIH | National Institute on Drug Abuse | 2025 | $188,482 | February 1, 2025 | January 31, 2030 | BHATIA, DEVIKA | reporter.nih.gov |
| Effects of Repeated CBD Administration on Cannabis Abuse-Liability and Analgesia: A Human Laboratory Study | NIH | National Institute on Drug Abuse | 2024 | $180,360 | August 1, 2024 | July 31, 2029 | HARRIS, HANNAH MARIE | reporter.nih.gov |
| Effects of Repeated CBD Administration on Cannabis Abuse-Liability and Analgesia: A Human Laboratory Study | NIH | National Institute on Drug Abuse | 2025 | $179,762 | August 11, 2025 | July 31, 2029 | HARRIS, HANNAH MARIE | reporter.nih.gov |
| Role of macrophages in CBD mediated attenuation of SEB-induced ARDS | NIH | National Institute of General Medical Sciences | 2022 to 2023 | $162,501 | February 1, 2022 | August 7, 2023 | WILSON, KIESHA | reporter.nih.gov |
| The impact of cannabinoids on inflammation, HIV viral load and symptoms of distress among persons living with HIV | NIH | National Institute on Drug Abuse | 2021 | $148,563 | August 1, 2019 | July 31, 2024 | OKAFOR, CHUKWUEMEKA NKEMAKONAM | reporter.nih.gov |
| Shared mechanisms of alcohol use disorder and Anxiety and effects of the endocannabinoid system | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $124,883 | August 1, 2021 | July 31, 2024 | MARTIN-WILLETT, RENEE | reporter.nih.gov |
| The Genetics of Cannabinoid Signaling: An Organismal Analysis | NIH | National Institute of General Medical Sciences | 2025 | $112,000 | September 1, 2025 | August 31, 2029 | LEAL, SANDRA MARIE | reporter.nih.gov |
| Structural investigation of a type III polyketide synthase involved in cannabinoid biosynthesis | NIH | National Center for Complementary & Integrative Health | 2022 to 2023 | $84,073 | June 30, 2022 | June 29, 2024 | GONZALEZ-DEWHITT, KRISTOFER R. | reporter.nih.gov |
| Respiratory health effects of aerosolized delta-8-THC and its oxidation products | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $78,800 | September 30, 2023 | September 29, 2025 | LOVE, CHARLOTTE ANN | reporter.nih.gov |
| Cannabidiol and buprenorphine: A poly-pharmacy approach to treat opioid use disorder | NIH | National Institute on Drug Abuse | 2025 | $78,052 | May 1, 2025 | August 30, 2026 | GALBO THOMMA, LINDSEY | reporter.nih.gov |
| Drug-drug interactions between cannabis and hydrocodone. | NIH | National Institute on Drug Abuse | 2022 to 2024 | $77,985 | August 16, 2022 | August 17, 2024 | COATES, SHELBY | reporter.nih.gov |
| Somatosensory corticospinal neurons as a biomarker for mind-body pain management strategies | NIH | National Center for Complementary & Integrative Health | 2021 | $70,458 | September 1, 2020 | August 31, 2022 | PAGE, JESSICA | reporter.nih.gov |
| Brain temperature and tissue microstructure in treatment-resistant epilepsy | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $58,059 | June 23, 2022 | August 31, 2023 | SHARMA, AYUSHE ALICIA | reporter.nih.gov |
| Nothing Micro About It: Investigating the Role of miRNAs and Cannabis Use in Cardiac Dysfunction among People Living with HIV | NIH | National Institute on Drug Abuse | 2025 | $54,000 | June 1, 2025 | May 31, 2027 | LARSON, MICHAELA | reporter.nih.gov |
| Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) | NIH | National Center for Complementary & Integrative Health | 2023 | $51,979 | September 27, 2019 | December 31, 2024 | RADHAKRISHNAN, RAJIV | reporter.nih.gov |
| Endocannabinoid Modulation of the HIV-Induced Microglial Inflammatory Response | NIH | National Institute on Drug Abuse | 2024 | $48,974 | June 17, 2024 | June 16, 2025 | ELLISON, ALYSHA | reporter.nih.gov |
| Investigating the Human Metabolism of the Minor Cannabinoid Cannabichromene | NIH | National Center for Complementary & Integrative Health | 2025 | $35,082 | February 1, 2025 | January 31, 2028 | WARD, ALEXANDRA | reporter.nih.gov |
| Exploring the Applicability of Potential Negative Allosteric Modulators at the Mu Opioid Receptor | NIH | National Institute on Drug Abuse | 2023 | $31,847 | January 5, 2023 | June 30, 2023 | BOSQUEZ-BERGER, TARYN | reporter.nih.gov |
Organizations
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 70 | $43,972,905 | 0 | $0 |
| 2024 | 72 | $50,641,651 | 0 | $0 |
| 2023 | 79 | $43,342,192 | 0 | $0 |
| 2022 | 73 | $42,438,833 | 0 | $0 |
| 2021 | 57 | $35,763,784 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.